Veracyte, Inc. (VCYT) Stock Analysis
Last updated Oct 27, 2026
Published Opportunity Closed
Position closed on Oct 1, 2026 at $44.19 — Technical . Return and QQQ are frozen from the exit date.
Health Check
Last analyzed Oct 23, 2026
- Financial Health 85
- Profitability 95
- Business Quality 75
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 82/100 — Elite Quality
A usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
Company overview
Veracyte, Inc. (VCYT) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Veracyte, Inc. 82/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 35.66
- Forward P/E 25.87
- EV/Revenue 6.1
Profitability
- Revenue Growth 15.5%
- Gross Margin 73.8%
- Operating Margin 15.3%
- Net Margin 20.4%
- ROE 8.8%
Financial strength
- Cash $485.23M
- Debt $40.11M
- Net Cash $445.13M
- Free Cash Flow $126.63M
- Current Ratio 9.16
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Illumina, Inc. Diagnostics & Research ILMN$279.47 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$70.53 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$50.17 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$232.00 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$242.56 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Sotera Health Company Diagnostics & Research SHC$18.49 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$161.86 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- BillionToOne, Inc. Diagnostics & Research BLLN$114.07 65 Health 65 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Veracyte, Inc. (VCYT).